Mirvetuximab soravtansine: A breakthrough in targeted therapy for platinum-resistant ovarian cancer

Author:

Kokori Emmanuel1,Olatunji Gbolahan1,Komolafe Rosemary1,Abraham Israel Charles1,Ukoaka Bonaventure2,Samuel Owolabi3,Ayodeji Akinmeji4,Ogunbowale Ibukunoluwa5,Ezenwoba Chidiogo6,Aderinto Nicholas7ORCID

Affiliation:

1. Department of Medicine and Surgery, University of Ilorin, Ilorin, Nigeria

2. Department of Internal Medicine, Asokoro District Hospital, Abuja, Nigeria

3. Department of Medicine and Surgery, Lagos State Health Service Commission, Lagos, Nigeria

4. Department of Medicine and Surgery, Olabisi Onabanjo University, Ogun, Nigeria

5. Department of Medicine and Surgery, Babcock University Teaching Hospital, Ogun, Nigeria

6. Department of Medicine and Surgery, Afe Babalola University, Ado-ekiti, Ekiti, Nigeria

7. Department of Medicine and Surgery, Ladoke Akintola University of Technology, Ogbomoso, Nigeria.

Abstract

Ovarian cancer, ranked as the second leading cause of gynecologic malignancy-related deaths globally, poses a formidable challenge despite advances in early detection and treatment modalities. This paper explores the efficacy and safety of mirvetuximab soravtansine, the first folate receptor alpha (FRα)-targeting antibody-drug conjugate, in platinum-resistant ovarian cancer expressing FRα. A review of 4 key studies involving 453 participants consistently demonstrates mirvetuximab soravtansine’s clinically meaningful antitumor activity and favorable safety profile. Clinical implications emphasize mirvetuximab soravtansine’s pivotal role in targeted therapy, especially for high FRα-expressing tumors, potentially reshaping platinum-resistant ovarian cancer management. The combination therapy approach introduces a novel dimension, suggesting enhanced therapeutic outcomes. Even in heavily pretreated patients, mirvetuximab soravtansine’s favorable tolerability positions it as a viable option. The reliability of archival tissue for FRα assessment simplifies patient selection, streamlining accessibility to targeted therapies. However, identified gaps, including limited diversity in patient populations, sparse quality of life data, and the need for long-term safety information, indicate areas for future research. Exploration of additional biomarkers predicting mirvetuximab soravtansine responsiveness is essential for personalized treatment.

Publisher

Ovid Technologies (Wolters Kluwer Health)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3